MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Eldelumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Eldelumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Eldelumab. |
| Estrone | Estrone may increase the thrombogenic activities of Eldelumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Eldelumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Eldelumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Eldelumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Eldelumab. |
| Estriol | Estriol may increase the thrombogenic activities of Eldelumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Eldelumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Eldelumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Eldelumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Eldelumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Eldelumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eldelumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Eldelumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Eldelumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Eldelumab. |
| Equol | Equol may increase the thrombogenic activities of Eldelumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Eldelumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Eldelumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Eldelumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Eldelumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Eldelumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Eldelumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Eldelumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Eldelumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Eldelumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Eldelumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Eldelumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Eldelumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eldelumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Eldelumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Eldelumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Eldelumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eldelumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eldelumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Eldelumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eldelumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Eldelumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Eldelumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Eldelumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eldelumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eldelumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Eldelumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eldelumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eldelumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Eldelumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eldelumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Eldelumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Eldelumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Eldelumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eldelumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eldelumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Eldelumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Eldelumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Eldelumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Eldelumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Eldelumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Eldelumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Eldelumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Eldelumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Eldelumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Eldelumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Eldelumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Eldelumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Eldelumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Eldelumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Eldelumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Eldelumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Eldelumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Eldelumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Eldelumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Eldelumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Eldelumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Eldelumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Eldelumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Eldelumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Eldelumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Eldelumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Eldelumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Eldelumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Eldelumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Eldelumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Eldelumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Eldelumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Eldelumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eldelumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Eldelumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Eldelumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Eldelumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Eldelumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Eldelumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Eldelumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Eldelumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Eldelumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eldelumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Canakinumab. |